MarketPulse

obesity market

7 articles
The Motley FoolThe Motley Fool··Adam Spatacco

Novo Nordisk's 72% Crash: Generational Buying Opportunity or Dangerous Trap?

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.
LLYNVOVKTXvaluation compressionmarket opportunity
The Motley FoolThe Motley Fool··Adria Cimino

Lilly's Retatrutide Could Cement Dominance in Surging Weight Loss Drug Market

Eli Lilly controls 60% of U.S. weight loss market with $11B+ quarterly revenue. Pipeline drug retatrutide showing 28% weight reduction could extend lead over Novo Nordisk.
LLYNVOclinical trialsweight loss drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk's Subscription Model Could Unlock Massive Obesity Market Despite Lilly Competition

Novo Nordisk launches tiered subscription pricing for Wegovy to expand obesity drug access. Stock trades at attractive 11x forward earnings amid market penetration opportunity.
LLYNVOGLP-1 drugsweight loss medications
BenzingaBenzinga··Vandana Singh

India's Generic Semaglutide Flood Slashes Ozempic Costs by 70%, Reshaping Global Obesity Market

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.
NVOHIMSRDYweight loss drugsobesity market
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly Expands Obesity Drug Lead With Clinical Win and Product Innovation

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.
PFELLYNVOVKTXclinical trialsGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs
BenzingaBenzinga··Erica Kollmann

Novo Nordisk Stock Drops 16% After CagriSema Misses Efficacy Target

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.
LLYNVOclinical trialobesity market